Ensign Peak Advisors
MXCT icon

Ensign Peak Advisors’s MaxCyte MXCT Stock Holding History

Ensign Peak Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-59,013
Closed -$230K – 1720
2024
Q3 		$230K Hold
59,013
– – ﹤0.01% 1686
2024
Q2 		$231K Hold
59,013
– – ﹤0.01% 1690
2024
Q1 		$247K Sell
59,013
-2,977
-5% -$14K ﹤0.01% 1699
2023
Q4 		$291K Buy
61,990
+3,600
+6% +$14K ﹤0.01% 1708
2023
Q3 		$182K Hold
58,390
– – ﹤0.01% 1729
2023
Q2 		$268K Hold
58,390
– – ﹤0.01% 1722
2023
Q1 		$289K Buy
58,390
+19,800
+51% +$97.5K ﹤0.01% 1717
2022
Q4 		$211K Buy
38,590
+19,050
+97% +$117K ﹤0.01% 1746
2022
Q3 		$127K Hold
19,540
– – ﹤0.01% 2028
2022
Q2 		$92K Hold
19,540
– – ﹤0.01% 1977
2022
Q1 		$137K Buy
+19,540
New +$133K ﹤0.01% 1967

Other funds holding MXCT

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ensign Peak Advisors's MXCT Position: Q4 2024 in Review

Ensign Peak Advisors sold out of MaxCyte (MXCT) in Q4 2024, closing a stake of 59,013 shares — an estimated $230K sold.

Ensign Peak Advisors first reported a position in MXCT in Q1 2022 and held it in 11 quarters. The position peaked at $291K in Q4 2023. 119 funds tracked by Wall St. Rank hold MXCT as of Q4 2024.

  • Ensign Peak Advisors reported no remaining MaxCyte position as of Q4 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 59,013 MaxCyte shares in Q4 2024, an estimated $230K.
  • Ensign Peak Advisors first reported a position in MaxCyte in Q1 2022 and held it in 11 quarters.
  • Ensign Peak Advisors's MaxCyte position peaked at $291K in Q4 2023.
  • 119 funds tracked by Wall St. Rank held MaxCyte as of Q4 2024.

Based on Ensign Peak Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.